Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL15568892

Nc1c(F)cccc1F.O=C(O)C(F)(F)F

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CES1 P23141 5/20 0.43
CES2 O00748 3/20 0.43
ALB P02768 1/20 0.41
KCNN4 O15554 2/20 0.39
BCHE P06276 1/20 0.39
TTR P02766 1/20 0.38
HDAC1 Q13547 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CHIT1 Q13231 1/20 0.37
G6PD P11413 1/20 0.36
CASP7 P55210 1/20 0.36
CASP6 P55212 1/20 0.36
KMT2A Q03164 1/20 0.36
DPP4 P27487 1/20 0.35
DPP7 Q9UHL4 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL15569991 0.87 KDM4E (0.41) CES1CES2
Trifluoroacetic Acid SCHEMBL3596920 0.82 CES1 (0.44) CES1CES2ALBKCNN4BCHE
Trifluoroacetic Acid SCHEMBL15568889 0.79 CES1 (0.50) CES1CES2ALBKCNN4L3MBTL1
SCHEMBL113475 0.78
SCHEMBL7008611 0.78 CES1 (0.44) CES1CES2ALBBCHEHDAC1
Urea SCHEMBL28869223 0.77 CES2 (0.46) CES1CES2ALBKCNN4BCHE
Trifluoroacetic Acid SCHEMBL30333105 0.76 CA1 (0.42) CES1CES2L3MBTL1
Hydrochloric Acid SCHEMBL7423355 0.75 CES2 (0.39) CES1CES2BCHEHDAC1
Methane SCHEMBL1703075 0.75 SMN1; SMN2 (0.43) CES1CES2BCHEHDAC1HDAC6
Bromide SCHEMBL29216576 0.75 CES2 (0.39) CES1CES2BCHEHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104540806-B Azaheterocycles as BIR2 and/or BIR3 inhibitors 霍夫曼-拉罗奇有限公司 2017-05-03 CN disclosed
US-9422332-B2 Azaheterocycles as BIR2 and/or BIR3 inhibitors HOFFMANN-LA ROCHE INC. (US) 2016-08-23 US disclosed
US-20150210739-A1 AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS HOFFMANN-LA ROCHE INC. 2015-07-30 US disclosed
EP-2885275-A1 AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-06-24 EP disclosed
CN-104540806-A Azaheterocycles as BIR2 and/or BIR3 inhibitors HOFFMANN LA ROCHE 2015-04-22 CN disclosed
WO-2014026882-A1 AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210739-A1 AZAHETEROCYCLES AS BIR2 AND/OR BIR3 INHIBITORS BIRC3, BIRC5, BIRC2 CES1 3902/4885CES2 4095/4885ALB 4632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.